• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intersect ENT slides on mixed bag Q1

May 10, 2021 By Sean Whooley

Intersect ENT updatedIntersect ENT (NSDQ:XENT) shares took a nosedive on first-quarter results that missed the consensus earnings forecast.

XENT shares were down -9.4% at $19.06 per share in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down -0.8%.

The Menlo Park, Calif.-based company posted losses of -$20 million, or -61¢ per share, on sales of $24.3 million for the three months ended March 31, 2021, for a -14.2% bottom-line slide on sales growth of 22.7%.

Adjusted to exclude one-time items, losses per share were -51¢, 9¢ behind Wall Street, where analysts were looking for sales of $23.5 million.

“We are pleased with our first-quarter results highlighted by the continued resilience in our Propel franchise despite the impact of COVID-related headwinds in the quarter. The continued and growing momentum in our Sinuva business is also a highlight of the quarter. Propel and Sinuva performance underscore the differentiated value proposition of our proprietary localized drug delivery sinus offerings and their clinical appropriateness across all settings of care,” Intersect ENT president & CEO Thomas A. West said in a news release. “Looking ahead, we anticipate sequential improvement throughout our business in the second quarter and beyond based on positive trends for elective and office-based sinus procedures.

“These encouraging trends, combined with our first-quarter performance and a broader product portfolio inclusive of navigation and sinus balloons, give us confidence to raise our 2021 revenue guidance. Moreover, we believe Intersect ENT is now well-positioned to achieve sustainable year-on-year growth.”

Intersect ENT said it now expects to log revenues of between $117 million and $121 million, an uptick from the previous projection of a range between $116 million and $120 million.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Wall Street Beat Tagged With: Intersect ENT Inc.

IN CASE YOU MISSED IT

  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS